-- 摩根士丹利週四在一份報告中指出，受人工智慧相關擔憂的影響，Appian (APPN) 的按席位計費模式正面臨嚴峻的市場環境。 該投資公司表示，這些擔憂主要集中在人工智慧可能抑制席位成長以及來自人工智慧原生應用的競爭。摩根士丹利指出，為了克服這些挑戰，Appian 可能需要加快營收成長，透過更高的訂閱等級實現人工智慧功能的貨幣化，並轉型為混合定價模式。 此外，該投資公司補充道，由於越來越多的投資者傾向於人工智慧的商業化，而非長期成長，應用軟體領域的投資環境仍然充滿挑戰。 摩根士丹利表示，Appian 預計將公佈穩健的第一季業績，並「適度」上調業績展望，但這「不太可能消除目前對該股構成壓力的廣泛爭議」。 Appian 將於 5 月 7 日公佈其第一季財務業績。 摩根士丹利將 Appian 的評級從“增持”下調至“中性”，並將目標價從 41 美元下調至 25 美元。 Appian的股價在周四的交易中下跌超過5%。
Price: $20.57, Change: $-1.16, Percent Change: -5.32%
Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.
Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%
Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%